International Journal of Cancer · 2023 · 13 citations · 28 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyOncogenesLung Cancer PharmacotherapyMolecular Tumor ProfilingOncogene MutationsOncogenic ProliferationOncogenic Signaling PathwaysSignal Transduction In CancerCell Viability AssaysCombination Drug TherapyHypomethylating Agent TherapyHypomethylating AgentsNon-small Cell Lung Cancer TherapyOncogenic Ras MutationsSmall Cell Lung Cancer TherapyTherapeutic Resistance Mechanisms
Non-small cell lung cancer (NSCLC) patients are often elderly or unfit and thus cannot tolerate standard aggressive therapy regimes. In our study, we test the efficacy of the DNA-hypomethylating agent decitabine (DAC) in combination with all-trans retinoic acid (ATRA), which has been shown to possess little systemic adverse effects. Screening a broad panel of 56 NSCLC cell lines uncovered a decrease in cell viability after the combination treatment in 77% of the cell lines. Transcriptomics, proteomics, proliferation and migration profiling revealed that fast proliferating and slowly migrating cell lines were more sensitive to the drug combination. The comparison of mutational profiles found oncogenic KRAS mutations only in sensitive cells. Additionally, different cell lines showed a heterogeneous gene expression response to the treatment pointing to diverse mechanisms of action. Silencing KRAS, RIG-I or RARB partially reversed the sensitivity of KRAS-mutant NCI-H460 cells. To study resistance, we generated two NCI-H460 cell populations resistant to ATRA and DAC, which migrated faster and proliferated slower than the parental sensitive cells and showed signs of senescence. In summary, this comprehensive dataset uncovers a broad sensitivity of NSCLC cells to the combinatorial treatment with DAC and ATRA and indicates that migration and proliferation capacities correlate with and could thus serve as determinants for drug sensitivity in NSCLC.
28
NIH Image to ImageJ: 25 years of image analysis
Caroline A Schneider, Wayne Rasband, Kevin W. Eliceiri · Nature Methods · 2012 · 65.2K citations
COSMIC: the Catalogue Of Somatic Mutations In Cancer
John Tate, Sally Bamford, Harry Jubb et al. · Nucleic Acids Research · 2018 · 5.3K citations · Full text
David Roulois, Helen Loo Yau, Rajat Singhania et al. · Cell · 2015 · 1.5K citations · Full text